Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 7/20 | 0.48 |
| ▸ | MEN1 | O00255 | 6/20 | 0.48 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.46 |
| ▸ | HPGD | P15428 | 2/20 | 0.46 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.46 |
| ▸ | RECQL | P46063 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 2/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.44 |
| ▸ | USP2 | O75604 | 1/20 | 0.44 |
| ▸ | HTT | P42858 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 3/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.43 |
| ▸ | PKM | P14618 | 2/20 | 0.43 |
| ▸ | ATM | Q13315 | 1/20 | 0.43 |
| ▸ | NPC1 | O15118 | 1/20 | 0.42 |
| ▸ | TP53 | P04637 | 1/20 | 0.42 |
| ▸ | RAB9A | P51151 | 1/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL483292 | 0.85 | ALDH1A1 (0.47) | KMT2AMEN1MAPK10ALDH1A1KDM4E | |
| SCHEMBL14399296 | 0.82 | ALDH1A1 (0.44) | KMT2AMEN1MAPK10ALDH1A1KDM4E | |
| SCHEMBL10474323 | 0.80 | MEN1 (0.37) | KMT2AMEN1ALDH1A1HPGDHSD17B10 | |
| SCHEMBL4906865 | 0.78 | KMT2A (0.54) | KMT2AMEN1MAPK10ALDH1A1KDM4E | |
| SCHEMBL198689 | 0.78 | ALDH1A1 (0.46) | KMT2AMEN1MAPK10ALDH1A1KDM4E | |
| SCHEMBL10997351 | 0.78 | KMT2A (0.46) | KMT2AMEN1MAPK10ALDH1A1KDM4E | |
| SCHEMBL4900637 | 0.78 | AXL (0.43) | KMT2AMEN1LMNAHTTMAPT | |
| SCHEMBL2896258 | 0.78 | AXL (0.43) | KMT2AMEN1ALDH1A1HTTMAPT | |
| SCHEMBL4057352 | 0.78 | KMT2A (0.46) | KMT2AMEN1MAPK10ALDH1A1KDM4E | |
| SCHEMBL3977601 | 0.77 | AXL (0.42) | KMT2AMEN1ALDH1A1HSD17B10MAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 44 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12534463-B2 | Substituted tricyclic compounds as FGFR inhibitors | INCYTE CORPORATION (US) | 2026-01-27 | — | — | US | disclosed |
| US-20240246974-A1 | SUBSTITUTED TRICYCLIC COMPOUNDS AS FGFR INHIBITORS | INCYTE CORPORATION | 2024-07-25 | — | — | US | disclosed |
| EP-4403216-A2 | SUBSTITUTED TRICYCLIC COMPOUNDS AS FGFR INHIBITORS | Incyte Holdings Corporation (US) | 2024-07-24 | — | — | EP | disclosed |
| EP-3822273-B1 | SUBSTITUTED TRICYCLIC COMPOUNDS AS FGFR INHIBITORS | INCYTE HOLDINGS CORP (US) | 2024-04-10 | — | — | EP | disclosed |
| US-11840534-B2 | Substituted tricyclic compounds as FGFR inhibitors | INCYTE CORPORATION (US) | 2023-12-12 | — | — | US | disclosed |
| US-20210380587-A1 | SUBSTITUTED TRICYCLIC COMPOUNDS AS FGFR INHIBITORS | INCYTE HOLDINGS CORPORATION | 2021-12-09 | — | — | US | disclosed |
| US-11053246-B2 | Substituted tricyclic compounds as FGFR inhibitors | INCYTE CORPORATION (US) | 2021-07-06 | — | — | US | disclosed |
| EP-3822273-A1 | SUBSTITUTED TRICYCLIC COMPOUNDS AS FGFR INHIBITORS | Incyte Holdings Corporation (US) | 2021-05-19 | — | — | EP | disclosed |
| US-20200377504-A1 | SUBSTITUTED TRICYCLIC COMPOUNDS AS FGFR INHIBITORS | INCYTE CORPORATION | 2020-12-03 | — | — | US | disclosed |
| EP-3495367-B1 | SUBSTITUTED TRICYCLIC COMPOUNDS AS FGFR INHIBITORS | INCYTE HOLDINGS CORP (US) | 2020-09-30 | — | — | EP | disclosed |
| WO-2004048386-A2 | THIENO[3,2-b]PYRIDINE-6-CARBONITRILES AND THIENO[2,3-b]PYRIDINE-5-CARBONITRILES AS PROTEIN KINASE INHIBITORS | WYETH (US) | 2004-06-10 | — | — | WO | disclosed |
| US-20030220365-A1 | Cell adhesion-inhibiting antiinflammatory compounds | STEWART ANDREW O (US) | 2003-11-27 | — | — | US | disclosed |
| US-6579882-B2 | Thieno(2,3-d)pyrimidine derivatives | ABBOTT LABORATORIES | 2003-06-17 | — | — | US | disclosed |
| US-20010020030-A1 | Cell adhesion-inhibiting antiinflammatory compounds | ABBVIE INC. | 2001-09-06 | — | — | US | disclosed |
| US-6232320-B1 | THIENO(2,3-C)PYRIDINE AND 5H-THIENO(2,3-C)PYRAN DERIATIVES | ABBOTT LABORATORIES | 2001-05-15 | — | — | US | disclosed |
| US-5468750-A | Antiinflammatory agents and autoimmune diseases | ELF SANOFI (FR) | 1995-11-21 | — | — | US | disclosed |
| US-5360799-A | Free radical inhibitors | ELF SANOFI (FR) | 1994-11-01 | — | — | US | disclosed |
| US-4935431-A | Substituted 7-amino-thienopyridine derivatives as gastric acid secretion inhibitors | SMITHKLINE BECKMAN INTERCREDIT B.V. (NL) | 1990-06-19 | — | — | US | disclosed |
| EP-0334491-A1 | Thienopyridines, process and intermediates for their preparation and pharmaceutical compositions containing them | SMITHKLINE BECKMAN INTERCREDIT B.V. (NL) | 1989-09-27 | — | — | EP | disclosed |
| WO-1989008112-A1 | THIENOPYRIDINES, PREPARATION, INTERMEDIATES AND PHARMACEUTICAL COMPOSITIONS | SMITHKLINE BECKMAN INTERCREDIT B.V. (NL) | 1989-09-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12534463-B2 | Substituted tricyclic compounds as FGFR inhibitors | FGFR3, FGFR1, FGFR4 | KMT2A 1681/4885MEN1 3656/4885MAPK10 2110/4885 |
| US-20010020030-A1 | Cell adhesion-inhibiting antiinflammatory compounds | ICAM1, VCAM1, EPCAM | KMT2A 4783/4885MEN1 4064/4885MAPK10 811/4885 |
| US-11840534-B2 | Substituted tricyclic compounds as FGFR inhibitors | FGFR3, FGFR1, FGFR2 | KMT2A 720/4885MEN1 4044/4885MAPK10 2176/4885 |
| US-20240246974-A1 | SUBSTITUTED TRICYCLIC COMPOUNDS AS FGFR INHIBITORS | FGFR3, FGFR1, FGFR2 | KMT2A 720/4885MEN1 4044/4885MAPK10 2176/4885 |
| US-20200377504-A1 | SUBSTITUTED TRICYCLIC COMPOUNDS AS FGFR INHIBITORS | FGFR3, FGFR1, FGFR2 | KMT2A 720/4885MEN1 4044/4885MAPK10 2176/4885 |
| US-20210380587-A1 | SUBSTITUTED TRICYCLIC COMPOUNDS AS FGFR INHIBITORS | FGFR3, FGFR1, FGFR2 | KMT2A 720/4885MEN1 4044/4885MAPK10 2176/4885 |
| US-20030220365-A1 | Cell adhesion-inhibiting antiinflammatory compounds | ICAM1, VCAM1, EPCAM | KMT2A 4783/4885MEN1 4064/4885MAPK10 811/4885 |
| US-11053246-B2 | Substituted tricyclic compounds as FGFR inhibitors | FGFR3, FGFR1, FGFR2 | KMT2A 720/4885MEN1 4044/4885MAPK10 2176/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.